Cargando…

Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen

OBJECTIVES: Antiresorptive treatment has been shown to impair mucosal cell proliferation, migration, and viability. However, in the clinic, antiresorptives are often used in combination with other drugs. We studied the effect of antiresorptives combined with a corticosteroid or antiestrogen on oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekholm, Heidi M., Löyttyniemi, Eliisa, Soukka, Tero, Rautava, Jaana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404500/
https://www.ncbi.nlm.nih.gov/pubmed/33443783
http://dx.doi.org/10.1002/cre2.382
Descripción
Sumario:OBJECTIVES: Antiresorptive treatment has been shown to impair mucosal cell proliferation, migration, and viability. However, in the clinic, antiresorptives are often used in combination with other drugs. We studied the effect of antiresorptives combined with a corticosteroid or antiestrogen on oral mucosal keratinocytes and fibroblasts. MATERIAL AND METHODS: Human gingival keratinocyte and fibroblast cell lines were exposed to bisphosphonates (BPs) and denosumab in different concentrations and durations together with an antiestrogen or corticosteroid. Changes in cell viability, proliferation and migration after exposures were measured. Data were evaluated with hierarchical linear mixed model for repeated measurements. RESULTS: Bisphosphonate exposure suppressed keratinocyte and fibroblast cell viability, proliferation, and migration in a time‐dependent manner. Combining a corticosteroid or antiestrogen with BPs further increased this negative effect. Denosumab alone had a mild positive effect on keratinocyte and fibroblast growth. When denosumab was combined with a corticosteroid or antiestrogen, cell growth was suppressed. CONCLUSIONS: Our results show that coexisting medications may increase the negative impact of BPs or denosumab on oral mucosal cells.